Technical Analysis for EXEL - Exelixis, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 37.27 | 4.54% | 1.62 |
Earnings due: Feb 4
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 4.54% | |
| Inside Day | Range Contraction | 4.54% |
| Alert | Time |
|---|---|
| New 52 Week High | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 10 hours ago |
| Up 3% | about 11 hours ago |
| Up 1 ATR | about 11 hours ago |
| Gapped Up (Full) | about 11 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/04/2025
Exelixis, Inc. Description
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Treatment Of Cancer Prostate Cancer Tyrosine Kinase Protein Kinase Inhibitor Thyroid Progressive Small Molecule Therapies Pivotal Cyclopropanes Receptor Tyrosine Kinase Resistant Prostate Cancer Thyroid Cancer Tyrosine Kinase Inhibitors Daiichi Sankyo Metastatic Castration Resistant Prostate Cancer Tyrosine Kinases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.31 |
| 52 Week Low | 20.015 |
| Average Volume | 2,197,742 |
| 200-Day Moving Average | 26.89 |
| 50-Day Moving Average | 34.98 |
| 20-Day Moving Average | 34.38 |
| 10-Day Moving Average | 34.74 |
| Average True Range | 1.00 |
| RSI (14) | 66.67 |
| ADX | 19.56 |
| +DI | 31.48 |
| -DI | 12.43 |
| Chandelier Exit (Long, 3 ATRs) | 34.31 |
| Chandelier Exit (Short, 3 ATRs) | 36.05 |
| Upper Bollinger Bands | 36.55 |
| Lower Bollinger Band | 32.20 |
| Percent B (%b) | 1.16 |
| BandWidth | 12.65 |
| MACD Line | 0.39 |
| MACD Signal Line | 0.08 |
| MACD Histogram | 0.3081 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.15 | ||||
| Resistance 3 (R3) | 38.96 | 38.13 | 38.84 | ||
| Resistance 2 (R2) | 38.13 | 37.65 | 38.23 | 38.73 | |
| Resistance 1 (R1) | 37.70 | 37.36 | 37.92 | 37.90 | 38.63 |
| Pivot Point | 36.88 | 36.88 | 36.99 | 36.98 | 36.88 |
| Support 1 (S1) | 36.45 | 36.40 | 36.66 | 36.64 | 35.91 |
| Support 2 (S2) | 35.62 | 36.10 | 35.72 | 35.81 | |
| Support 3 (S3) | 35.19 | 35.62 | 35.70 | ||
| Support 4 (S4) | 35.39 |
